Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × ARRY-334543 × Gastrointestinal × Clear all
NCT03130790 2022-02-15

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

ASLAN Pharmaceuticals

Phase 2/3 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03093870 2021-08-03

TreeTopp

ASLAN Pharmaceuticals

Phase 2/3 Completed
151 enrolled 18 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms

NCT02609958 2018-05-29

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

ASLAN Pharmaceuticals

Phase 2 Completed
32 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT00862524 2012-10-04

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Array BioPharma

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡